Physician profile
Carol D Crouch-Ross
NPI 1053466946
$24,387.27
in general payments reported to CMS, 2019-2025
29 companies · $4,725 in 2025
The $4,725 reported for 2025 was more than what 97% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,337 · 2020: $1,544 · 2021: $2,904 · 2022: $3,050 · 2023: $4,046 · 2024: $3,781 · 2025: $4,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,545.15 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $4,523.49 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $3,317.34 | 2019-2025 | Rexulti, Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $3,079.63 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,584.44 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,681.04 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,463.31 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $942.65 | 2022-2025 | Auvelity |
| Corium, LLC | $808.84 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $774.42 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $740.69 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $719.83 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $648.97 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $493.96 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $382.32 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $366.56 | 2019-2025 | Dyanavel Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $283.06 | 2021-2025 | Lybalvi, Aristada |
| Shire North American Group INC | $272.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $258.52 | 2019-2021 | |
| Eisai INC. | $216.05 | 2021-2022 | |
| Neos Therapeutics, Lp | $207.93 | 2019-2025 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $175.12 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $122.94 | 2022-2025 | Quviviq, Quviviq |
| Avanir Pharmaceuticals, INC. | $95.63 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $58.46 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $50.46 | 2019 | |
| Arbor Pharmaceuticals, INC. | $47.49 | 2019 | |
| Validus Pharmaceuticals LLC | $35.20 | 2019-2023 | Equetro |
| Livanova USA, INC. | $23.10 | 2021 | |
| Noven Therapeutics, LLC | $13.47 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Crouch-Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.